Keros Therapeutics, Inc. announced that five abstracts will be presented from its hematology program at the 65th American Society of Hematology Annual Meeting and Exposition to be held in person and virtually from December 9 through 12, 2023.
LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from its hematology program at the 65th American Society of Hematology (“ASH”) Annual Meeting and Exposition to be held in person and virtually from December 9 through 12, 2023. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome (“MDS”) and one in patients with myelofibrosis.
The following abstracts were posted to the ASH website on November 2, 2023, 9:00 a.m. Eastern time.
Clinical Presentations
“Durable Clinical Benefit with KER-050 treatment: Findings From an Ongoing Phase 2 Study in Participants with Lower-Risk MDS”
- Publication Number: 196
- Session Name: 637. MDS Clinical and Epidemiological: Treatment Options and Decision making in Low Risk MDS
- Date: Saturday, December 9, 2023
- Presentation Time: 2:00 p.m. – 4:00 p.m. Pacific time
“Modulation of TGF-β Superfamily Signaling By KER-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia”
- Publication Number: 3185
- Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
- Date: Sunday, December 10, 2023
- Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time
“KER-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche”
- Publication Number: 1089
- Session Name: 102. Iron Homeostasis and Biology
- Date: Saturday, December 9, 2023
- Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time
Preclinical Presentations
“RKER-050, A Modified Activin Receptor Type IIA Ligand Trap, Promoted Erythropoiesis in a Murine Model of Myelofibrosis”
- Publication Number: 4524
- Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
- Date: Monday, December 11, 2023
- Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time
“RKER-216 Reversed Microcytic Anemia in a Mouse Model of Iron Refractory Iron Deficiency Anemia”
- Publication Number: 2466
- Session Name: 102. Iron Homeostasis and Biology: Poster II
- Date: Sunday, December 10, 2023
- Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time
About KER-050
Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing large and small molecules that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ fourth product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believe,” “can,” “look forward,” “potential” and/or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ presentation plans for the upcoming ASH Annual Meeting and Exposition. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, KER-050, KER-047, KER-012 and KER-065; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2023, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
